MAP2K7 and melanoma: While MEK-inhibitors as monotherapy have been tested in NRAS mutant melanoma patients and have shown a minor advantage in progression free survival (PFS) without an impact on overall survival [16], they are still used in selected cases lacking alternative treatment options and result in additional benefit in selected cases [17].